middle.news
Alterity Therapeutics Secures FDA Nod for Single Phase 3 Trial in Multiple System Atrophy
10:00am on Thursday 30th of July, 2026 AEST
•
Biotechnology
Read Story
Alterity Therapeutics Secures FDA Nod for Single Phase 3 Trial in Multiple System Atrophy
10:00am on Thursday 30th of July, 2026 AEST
Key Points
FDA confirms single pivotal Phase 3 trial for ATH434
Phase 3 trial to enrol ~200 patients with 12-month treatment
A$37.3 million cash on hand with A$3.98 million R&D tax refund
Board strengthened with Ann Cunningham’s appointment
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE